Is BMY Stock Undervalued?

A comprehensive valuation analysis of Bristol-Myers Squibb Company (BMY) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated June 13, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

187078806674.1% upside potential

Based on our analysis, Bristol-Myers Squibb Company appears to be potentially undervalued at the current price of $57.27. Our fair value estimate of $107140032639.51 suggests upside potential of approximately 187078806674.1%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing BMY relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

17.49

Moderate

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: At 17.49x earnings, BMY is trading near the typical market average of 15-20x.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Bristol-Myers Squibb Company stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$57.27

Fair Value Estimate

$107140032639.51

Implied Return+187078806674.1%

Our DCF model suggests BMY may be undervalued by approximately 187078806674.1%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Bristol-Myers Squibb Company (BMY) appears to be undervalued at $57.27. With a fair value estimate of $107140032639.51, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.